DPA
VRTX icon

Delphi Private Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Delphi Private Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5
Closed – – 114
2017
Q2 		$0 Buy
+5
New +$602 ﹤0.01% 134
2016
Q3 		– Sell
-3
Closed – – 549
2016
Q2 		$0 Sell
3
-2
-40% -$173 ﹤0.01% 551
2016
Q1 		$0 Hold
5
– – ﹤0.01% 411
2015
Q4 		$1K Buy
+5
New +$604 ﹤0.01% 338

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Delphi Private Advisors's VRTX Position: Q3 2017 in Review

Delphi Private Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 5 shares.

Delphi Private Advisors first reported a position in VRTX in Q4 2015 and held it in 4 quarters. The position peaked at $1K in Q4 2015. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • Delphi Private Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Delphi Private Advisors sold 5 Vertex Pharmaceuticals shares in Q3 2017.
  • Delphi Private Advisors first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Delphi Private Advisors's Vertex Pharmaceuticals position peaked at $1K in Q4 2015.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Delphi Private Advisors's 13F filing for Q3 2017, filed 16 Oct 2017.